insights_auto
Nega MVIR oshdi 2,33%?
Batafsil oʻrganishchevron_right
MVIR:STO
Medivir AB
1,49Â SEK
arrow_upward
+2,33%(+0,034) 1K
9-okt, 17:29:42 (GMT+2) · SEK
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoMVIR tikeri uchun statistika yaratilmoqda...
Ochish
1,47Â SEK
Yuqori
1,50Â SEK
Past
1,45Â SEK
Bozor kapitali
932,52Â mln
Oʻrtacha hajm
1,41Â mln
Hajmi
1,73Â mln
52 haftalik eng yuqori
2,88Â SEK
52 haftalik eng past
0,34Â SEK
Aksiya boʻyicha daromad
-0,37Â SEK
Muomaladagi aksiyalar
624,18Â mln
Xodimlar soni
6
Ochish
1,47Â SEK
Yuqori
1,50Â SEK
Past
1,45Â SEK
Bozor kapitali
932,52Â mln
Oʻrtacha hajm
1,41Â mln
Hajmi
1,73Â mln
52 haftalik eng yuqori
2,88Â SEK
52 haftalik eng past
0,34Â SEK
Aksiya boʻyicha daromad
-0,37Â SEK
Muomaladagi aksiyalar
624,18Â mln
Xodimlar soni
6
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
marketscreener.com
·
38 daqiqa oldin
Wall Street posts gains with earnings, inflation data on tap
TradingView
·
1 soat oldin
Lb Pharmaceuticals Reports Inducement Grants To New Employee Under Nasdaq Listing Rule 5635(C)(4)
Profil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Medivir AB haqida